FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules

• Published in: Clinical and experimental medicine 2019-11, Vol.19 (4), p.557-564
• Main Authors: Kuang, Muyu, Peng, Yizhou, Tao, Xiaoting, Zhou, Zilang, Mao, Hengyu, Zhuge, Lingdun, Sun, Yihua, Zhang, Huibiao
• Format: Article
• Language: English
• Subjects: Benign; Biomarkers; Biomarkers, Tumor - blood; Diagnosis; Diagnostic Tests, Routine; Exosomes; Exosomes - chemistry; Female; Fibrinogen - analysis; Hematology; Humans; Internal Medicine; Lung Neoplasms - diagnosis; Lung Neoplasms - pathology; Lung nodules; Male; Medicine; Medicine & Public Health; Oncology; Original Article; Plasma - chemistry; Proteomics; ROC Curve; Sensitivity and Specificity; Surgery
• ISSN: 1591-8890; 1591-9528
• DOI: 10.1007/s10238-019-00581-8

Previous proteomic analysis (label-free) of plasma exosomes revealed that the expression of FGG and FGB was significantly higher in the malignant pulmonary nodules group, compared to the benign pulmonary nodules group. The present study was performed to evaluate the role of plasma exosomal proteins FGB and FGG in the diagnosis of benign and malignant pulmonary nodules. We examined the expression levels of FGB and FGG in plasma exosomes from 63 patients before surgery. Postoperative pathological diagnosis confirmed that 43 cases were malignant and 20 cases were benign. The ROC curve was used to describe the sensitivity, specificity, area under the curve (AUC) of the biomarker and the corresponding 95% confidence interval. We confirmed that the expression levels of FGB and FGG were higher in the plasma exosomes of malignant group than in the benign group. The sensitivity and AUC of FGB combined with FGG detection to determine the nature of pulmonary nodules are superior to single FGB or FGG detection. FGB and FGG might represent novel and sensitive biomarker to distinguish benign from malignant pulmonary nodules.